Consructio Needs Over Next Five Years Total Estimated $696 Million; NCI Share-$132 Million
In Brief: NCAB Still Without New Appinees As Carter, Califano Delay Drags On; Keele to U. Kansas
New Staff Proposals For Comprehensive Center Recognition Considered By NCAB
DCT Announces Neutron Therapy RFP Available
Rall Says NTP to Put 50-75 Chemicals On Long Term Tests
NCAB Subcommittee Worries About Board’s Makeup
Court Forces CPSC To Reopen Carcinogen Policy
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation
- FDA’s OCE publishes three final guidances to increase clinical trial enrollment
